| Cat. No. |
Product Name |
Information |
| PC-61139 |
GPA 512
STAT3 inhibitor
|
GPA512 is the orally bioavailable prodrug of Galiellalactone, a direct inhibitor of STAT3, prevents the transcription of STAT3 regulated genes. |
| PC-61125 |
STAT5 inhibitor 17f
STAT5 inhibitor
|
A novel potent, selective inhibitor of phosphorylation and transcriptional activity of STAT5, but not STAT3, AKT, or Erk1/2 phosphorylation. |
| PC-61033 |
Erasin
STAT3 inhibitor
|
Erasin is a potent, selective STAT3 inhibitor with IC50 of 9.7 uM, inhibits tyrosine phosphorylation of STAT3 with selectivity over STAT5 and STAT1 in cell-based assays. |
| PC-60938 |
LLL12
STAT3 inhibitor
|
LLL12 is a nonpeptide, cell-permeable STAT3 inhibitor that binds directly to the pTyr705 binding site of the STAT3 monomer. |
| PC-60934 |
HJC0152
STAT3 inhibitor
|
HJC0152 is a potent, orally bioavailable STAT3 signaling inhibitor that exhibits promising antitumor effects in vitro and in vivo via inactivating STAT3 and downstream miR-21/β-catenin axis. |
| PC-60904 |
STAT3 inhibitor C188
STAT3 inhibitor
|
STAT3 inhibitor C188 (CPD188) is a potent, selective STAT3 inhibitor that blocks STAT3 binding to its phosphopeptide ligand (IC50=20 uM) and inhibits IL-6-mediated phosphorylation of STAT3. |
| PC-60659 |
ML116
STAT3 inhibitor
|
ML116 is a selective STAT3 inhibitor with IC50 of 4.2 uM, does not inhibit STAT1, STAT5, or NFkB signaling pathways (IC50>50 uM). |
| PC-60658 |
CPA7
STAT3 inhibitor
|
STAT3 inhibitor CPA7 is a platinum-containing compound that disrupts STAT3 signaling, inhibits cell growth and induces apoptosis in STAT3-activated cancer cells. |
| PC-60500 |
HJC0416
STAT3 inhibitor
|
HJC0416 is an orally bioavailable small-molecule STAT3 inhibitor. |
| PC-60456 |
Cucurbitacin I
JAK/STAT3 inhibitor
|
Cucurbitacin I (JSI-124) is a triterpenoid compound that potently and selectively inhibits JAK/STAT3 pathway, suppresses the levels of phosphotyrosine STAT3 in A549 cell with IC50 of 500 nM. |
| PC-60417 |
Debio 0617B
Multi-kinases inhibitor
|
Debio 0617B is a first-in-class, multi-kinase inhibitor that targets pSTAT3 and/or pSTAT5 in cancer cells through combined inhibition of JAK, SRC, ABL, and class III/V RTKs (Kd<100 nM). |
| PC-42174 |
BP-1-102
STAT3 inhibitor
|
BP-1-102 is an orally bioavailable, small-molecule inhibitor of STAT3 with Kd of 504 nM. |
